A Phase II Trial of the Oral FGF Receptor Inhibitor AZD4547 as 2nd or 3rd Line Therapy in Malignant Pleural Mesothelioma - Trial in Progress

被引：2

作者：

Lam, Wei-Sen ^{[1
]}

Lee, Y. C. Gary ^{[2
]}

Creaney, Jenette ^{[3
]}

Muruganandan, Sanjeevan ^{[4
]}

Millward, Michael ^{[2
]}

Read, Catherine ^{[5
]}

Nowak, Anna ^{[2
]}

机构：

[1] Sir Charles Gairdner Hosp, Med Oncol, Perth, WA, Australia

[2] Univ Western Australia, Sch Med & Pharmacol, Crawley, WA, Australia

[3] Natl Ctr Asbestos Related Dis, Sch Med & Pharmacol, Perth, WA, Australia

[4] Sir Charles Gairdner Hosp, Resp Med, Perth, WA, Australia

[5] Inst Resp Hlth, Pleural Med, Perth, WA, Australia

来源：

关键词：

Mesothelioma; fibroblast growth factor; clinical trial; second line treatment;

D O I：

10.1016/j.jtho.2016.11.1519

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.06-026

引用

页码：S1087 / S1087

页数：1